Laurel Wealth Advisors LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 25.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,266 shares of the biopharmaceutical company’s stock after selling 4,575 shares during the period. Laurel Wealth Advisors LLC’s holdings in Pfizer were worth $382,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of PFE. Briaud Financial Planning Inc bought a new position in shares of Pfizer during the 3rd quarter worth about $30,000. Mizuho Securities Co. Ltd. bought a new position in shares of Pfizer during the 3rd quarter worth about $34,000. VisionPoint Advisory Group LLC boosted its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC boosted its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer during the 4th quarter worth about $36,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Stock Performance
Shares of Pfizer stock traded up $0.14 during mid-day trading on Friday, hitting $25.40. 46,526,457 shares of the stock were exchanged, compared to its average volume of 34,120,812. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The company has a 50-day simple moving average of $26.96 and a 200 day simple moving average of $28.36. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The company has a market capitalization of $143.83 billion, a P/E ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61.
Pfizer Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.61%. Pfizer’s payout ratio is currently 466.67%.
Analyst Upgrades and Downgrades
PFE has been the topic of a number of research analyst reports. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $36.33.
Check Out Our Latest Stock Analysis on PFE
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Five stocks we like better than Pfizer
- What is Insider Trading? What You Can Learn from Insider Trading
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- Compound Interest and Why It Matters When Investing
- MarketBeat Week in Review – 4/22 – 4/26
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.